$-0.28 EPS Expected for OncoSec Medical (ONCS), 3 Analysts Are Bullish Carclo plc (LON:CAR) Last Week

May 22, 2017 - By Vivian Park

Among 3 analysts covering Carclo PLC (LON:CAR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Carclo PLC had 37 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, October 14 by FinnCap. The firm has “Buy” rating by Peel Hunt given on Wednesday, August 31. Peel Hunt maintained the shares of CAR in report on Tuesday, January 12 with “Buy” rating. The firm earned “Buy” rating on Thursday, September 29 by Peel Hunt. Peel Hunt maintained Carclo plc (LON:CAR) on Tuesday, April 11 with “Buy” rating. On Thursday, February 4 the stock rating was maintained by FinnCap with “Buy”. The firm has “Buy” rating given on Tuesday, November 15 by Peel Hunt. The stock has “Buy” rating by N+1 Singer on Friday, October 14. The firm has “Buy” rating given on Tuesday, November 17 by Peel Hunt. Peel Hunt maintained Carclo plc (LON:CAR) rating on Tuesday, January 31. Peel Hunt has “Buy” rating and GBX 190 target. See Carclo plc (LON:CAR) latest ratings:

11/04/2017 Broker: N+1 Singer Rating: Buy Old Target: GBX 161.00 New Target: GBX 161.00 Maintain
11/04/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
30/03/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
02/03/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
31/01/2017 Broker: N+1 Singer Rating: Buy Old Target: GBX 161.00 New Target: GBX 161.00 Maintain
31/01/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
11/01/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
05/01/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 190.00 New Target: GBX 190.00 Maintain
19/12/2016 Broker: FinnCap Rating: Buy Old Target: GBX 138.00 New Target: GBX 138.00 Maintain

Analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to report $-0.28 EPS on June, 8.They anticipate $0.09 EPS change or 24.32% from last quarter’s $-0.37 EPS. After having $-0.27 EPS previously, OncoSec Medical Inc’s analysts see 3.70% EPS growth. The stock increased 4.26% or $0.039 on May 19, reaching $0.949. About shares traded. OncoSec Medical Inc (NASDAQ:ONCS) has risen 6.00% since April 22, 2017 and is uptrending. It has by 0.00% the S&P500.

Among 2 analysts covering OncoSec Medical (NASDAQ:ONCS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 2 analyst reports since March 9, 2016 according to SRatingsIntel. The stock of OncoSec Medical Inc (NASDAQ:ONCS) earned “Buy” rating by H.C. Wainwright on Wednesday, March 9. The firm earned “Buy” rating on Thursday, July 21 by Rodman & Renshaw.

OncoSec Medical Incorporated is a biotechnology company. The company has market cap of $20.64 million. The Firm is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. It currently has negative earnings. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

About 5,581 shares traded. Carclo plc (LON:CAR) has risen 6.00% since April 22, 2017 and is uptrending. It has by 0.00% the S&P500.

Carclo plc is engaged in the supply of fine tolerance, injection molded plastic components, mainly for medical products. The company has market cap of 105.31 million GBP. The Firm is also engaged in the design and supply of specialized injection molded light-emitting diode lighting systems to the automotive industry. It has a 32.35 P/E ratio. The Firm operates through four divisions: Technical Plastics, LED Technologies, Aerospace and CIT Technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: